Literature DB >> 17205224

Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease.

S Ottaviani1, M Tinazzi, I Pasquin, W Nothdurfter, G Tomelleri, E Fincati, G Nordera, G Moretto, A Fiaschi, N Smania, P Giorgetti, A Antonini.   

Abstract

We used qualitative visual assessment and semiquantitative measures of striatal DAT binding using [(123)I]FP-CIT-SPET in 85 patients with Parkinson's disease (PD). We compared these two assessments and their correlation with PD clinical progression. SPET imaging was visually classified by a nuclear medicine physician as normal or abnormal pattern grade I, II and III, in relation to a different degree of radioligand reduction uptake. Nineteen patients presented abnormal grade I (group 1), 53 grade II (group 2) and 13 grade III (group 3). The UPDRS III motor score, the H-Y score, the rigidity and bradykinesia subscores were significantly different among the three groups. Post hoc analysis showed that all values of these clinical parameters were higher in group 3 than in 2 and 1. All clinical indices were also significantly higher in group 2 than in group 1. This means that groups 3 and 2 were clinically more severely affected. No significant differences among the 3 groups were observed for age or duration of disease. Values of the mean striatum uptake were also significantly different among the three groups. Post hoc analysis revealed significantly lower values of the mean striatum uptake in group 3 with respect to groups 2 and 1; values were also significantly lower in group 2 than in group 1. We conclude that our findings of good consistency between visual and semi-quantitative assessment may help simplify the evaluation of striatal DAT binding in PD in a clinical routine setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17205224     DOI: 10.1007/s10072-006-0718-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  12 in total

1.  The Face Behind the Mask: Can Imaging Help Early Parkinson Diagnosis?

Authors:  Angelo Antonini
Journal:  Mov Disord Clin Pract       Date:  2014-11-28

2.  Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Authors:  Elina Mäkinen; Juho Joutsa; Jarkko Johansson; Maija Mäki; Marko Seppänen; Valtteri Kaasinen
Journal:  J Neural Transm (Vienna)       Date:  2016-06-20       Impact factor: 3.575

3.  Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET.

Authors:  Moonyoung Chung; Young Seok Park; Ji Seon Kim; Yun Joong Kim; Hyeo Il Ma; Su Jin Jang; Ryoong Huh; Hyun Sook Kim; Won-Chan Kim
Journal:  Jpn J Radiol       Date:  2015-05-08       Impact factor: 2.374

4.  Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease?

Authors:  Julie A Robichaud; Kerstin D Pfann; Sue Leurgans; David E Vaillancourt; Cynthia L Comella; Daniel M Corcos
Journal:  Clin Neurophysiol       Date:  2008-12-11       Impact factor: 3.708

5.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.

Authors:  Francisco J Diaz-Corrales; Salome Sanz-Viedma; David Garcia-Solis; Teresa Escobar-Delgado; Pablo Mir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

6.  Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases.

Authors:  Jun Ueda; Hajime Yoshimura; Keiji Shimizu; Megumu Hino; Nobuo Kohara
Journal:  Neurol Sci       Date:  2017-04-07       Impact factor: 3.307

7.  Establishing On-Site Reference Values for (123)I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions.

Authors:  Nicolas Nicastro; Valentina Garibotto; Antoine Poncet; Simon Badoud; Pierre R Burkhard
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

8.  Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism.

Authors:  Michele Tinazzi; Angelo Antonini; Tommaso Bovi; Isabella Pasquin; Maria Steinmayr; Giuseppe Moretto; Antonio Fiaschi; Sarah Ottaviani
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

9.  Clinical neuroimaging: a matter of biophysics and logistics.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 10.057

10.  The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.

Authors:  Angelo Antonini
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.